Market Research Report
Investigation Report on Chinese Compound Amino Acid Market 2021-2025
|Investigation Report on Chinese Compound Amino Acid Market 2021-2025|
Published: May 28, 2021
China Research and Intelligence
Content info: 50 Pages
Delivery time: 1-2 business days
Compound Amino Acid is clinically used for patients with insufficient protein intake, malabsorption, and other amino acids that cannot meet the requirements of body metabolism. It was developed by Japan Ajinomoto Pharmaceutical Co., Ltd. At present, more than 20 categories of Compound Amino Acid injections have been approved in China. By 2020, in addition to Guangdong Litai Pharmaceutical Co., Ltd. in the Chinese Compound Amino Acid market, there are 34 companies, such as Guangzhou Green Cross Pharmaceutical Co., Ltd., Hubei Bantian Pharmaceutical Co., Ltd., Fujian Tianquan Pharmaceutical Co., Ltd., and Liaoning Haisco Pharmaceutical Co., Ltd.
According to CRI analysis, the sales of Compound Amino Acids in the Chinese market have basically maintained a slow growth from 2016 to 2020, reaching about 1.53 billion in 2020, and the CAGR from 2016 to 2020 is about 1.8%. The main reason is that the clinical demand for Compound Amino acids is relatively stable.
CRI predicts that with the development of Compound Amino Acid categories from 2021 to 2025, the number of indications will increase so that sales and sales volume have potential for growth. Moreover, with the addition of new manufacturers in the Chinese Compound Amino Acid market, market competition will become increasingly fierce and sales will increase as prices fall.